The seventh edition of the American Joint Committee on Cancer (AJCC) staging system introduced tumour location for the first time as an determinant of stage grouping in pathological T2N0M0 and T3N0M0 ( pT2-3N0M0) oesophageal squamous cell carcinoma (OSCC). However, the new modification remains controversial. The objective of this study was to investigate the correlation between tumour location and postoperative long-term survival in patients with OSCC in China.
INTRODUCTION
Oesophageal squamous cell carcinoma (OSCC), one of the most virulent malignancies and a major cause of cancer-related deaths worldwide, is the predominant histopathological type in East Asian countries [1] . In China, OSCC has ranked the fourth of cancer-related mortality [2] . Despite recent advances in early diagnosis and treatment have led to improved survival, the clinical outcome and the overall survival of OSCC patients still remain poor. Such pessimistic outcome indicates that the rational assessment and management of this disease requires an effective staging system to determine the proper treatment and predict long-term survival. TNM staging of oesophageal cancer, first introduced in 1977, is a simple and effective tool to provide accurate estimate of the prognosis, and aid the clinicians in planning treatment [3, 4] .
The new staging system, using data from Worldwide Esophageal Cancer Collaboration (WECC) and presented in the seventh edition of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) Staging Manual, had a database of 4627 patients who underwent oesophagectomy alone from 13 institutions all over the world. Unlike the previous staging systems, the new AJCC staging system is not only based on the anatomical extent (T, N and M), but also includes histopathological cell type, histological grade and tumour location and establishes a revision of the N-classification from site-dependent to numerically based staging [5] . This renders the current AJCC staging system more reliable than previous editions [6] .
However, oesophageal cancer in Eastern patients is known to differ biologically from oesophageal cancer in Western countries, and more than 50% of patients with oesophageal cancer are Chinese [7] . Unfortunately, Asian patients constitute only 25.2% (1168/4627) of the database used to elaborate the seventh AJCC staging system for oesophageal cancer [6] . Because OSCC is the most common pathological type in the East, several reports on the correlation between tumour location and postoperative survival have been published, based mostly on Asian populations. Most of the studies found tumour location did not adequately differentiate patients into different staging category subgroups with respect to overall survival in OSCC, which was contrary to the data for the seventh AJCC staging system. Therefore, we re-evaluated the new AJCC/UICC staging system in a single-centre patient collective of 988 consecutive surgically treated patients to further validate the relationship between tumour location and overall survival for operable OSCC. The purpose is to assess whether tumour location should be included as a factor in staging thoracic OSCC patients.
MATERIALS AND METHODS

Patient selection
From January 1984 to December 1995, a total of 2015 patients with oesophageal cancer who underwent oesophagectomy were selected from our Thoracic Surgery Database. Inclusion criteria for the study were (i) OSCC, (ii) the primary tumour originated in the thoracic oesophagus, (iii) radical resection (R0), (iv) at least 12 lymph nodes were dissected, (v) the records contained complete clinical data and (vi) at least 10 years of follow-up data. Patients with the following criteria were excluded: (i) non-squamous cell morphology, (ii) those who had received any form of neoadjuvant or adjuvant treatment, (iii) with concomitant oesophageal cancer and malignancy in other organs, (iv) less than 12 lymph nodes dissected according to the seventh AJCC staging system, (v) with incomplete clinical information that cannot be used to restage according to the new staging system and (vi) hospital death, which was defined as death within 30 days after the operation or any time after the operation when death occurred in the hospital. Our study had been approved for use in research by the Institutional Review Board of West China Hospital, Sichuan University. The need for informed consent from patients was waived because of its retrospective design and prohibition of any identifiable individual data utilization.
Surgical procedure
A transthoracic oesophagectomy with end-to-side oesophagogastric anastomosis and lymphadenectomy was performed by means of left or right thoracotomy. Usually, a left posterolateral thoracotomy was performed when tumour located below the aortic arch, and a right thoracotomy was utilized for tumour located above the aortic arch. A standard mediastinal lymphadenectomy (subcarinal, left and right bronchial, lower posterior mediastinum, pulmonary ligament and paraoesophageal and thoracic duct) was performed in all patients.
Staging and location
Staging of OSCC has been extensively changed and improved in the seventh edition of the AJCC/UICC Cancer Staging Manuals. All of the patients included in the study were restaged according to the new staging manual. Tumour location was redefined as that in the current AJCC Cancer Staging Manual.
Follow-up
A regular follow-up was continued up to June 1996 or until death if this occurred earlier, with a follow-up rate of 92.4%. The mean follow-up was 77.0 months (range, 2.0-129.0 months). Seventy-five patients were lost to follow-up (7.6%). The routine examinations included physical check-up, blood chemistry analysis, ultrasonography, chest computed tomography, oesophagography and endoscopy in necessity. If the patient had specific symptoms, a further detailed assessment was performed immediately.
Statistical analysis
All statistical analyses were performed using the SPSS 16.0 software package (SPSS, Inc., Chicago, IL, USA). Overall survival time was calculated from the date of operation to the date of death or most recent follow-up. The values were presented as median (range) or mean ± standard deviation. The Kaplan-Meier method was used to estimate the survival rate. Differences between patient groups with respect to their survival were assessed using log-rank tests, and the difference was considered to be statistically significant if P < 0.05. Apart from patients' sex and age, those covariates with a P-value of less than 0.1 in univariate survival analysis were entered into multivariate Cox proportional hazard analysis to assess the independent influence of these covariates. Backward stepwise elimination of variables was used to construct the final model. Patients who were lost or died of other disease during the follow-up period were considered as a censored value.
RESULTS
Patient characteristics
Of 2015 oesophagectomies for oesophageal cancer performed in our department between January 1984 and December 1995, 1874 (93.0%) were histologically diagnosed as OSCC; Of these histologically confirmed diagnoses, 1386 (68.7%) underwent radical resection and were neither proceeded nor followed by adjuvant chemotherapy or radiotherapy. We excluded 11 (0.5%) patients with concomitant malignancies in other organs, 212 (10.5%) with less than 12 lymph nodes dissected, 26 (1.3%) hospital death, 92 (4.6%) for the lack of complete clinical information and 57 (2.8%) for two or more of these reasons, leaving a study group of 988 patients [635 (64.3%) males and 353 (35.7%) females], in which 632 (64.0%) were pathological T2N0M0 and T3N0M0 patients [ pT2-3N0M0, 399 (63.1%) males and 233 (36.9%) females, respectively]. The median follow-up time for the entire 988 patients was 77.0 months (range, 62.0-129.0 months). The median age was 53 years (range: 25-76 years), with the majority of tumours in the middle thoracic segment (774, 78.3%). The distribution of tumour grades was basically uniform, with approximately half (483, 48.9%) of the patients being moderately differentiated (G2). The median tumour length was 5 cm, and was therefore used as the cut-off value to define oesophageal tumour length (<5 vs >5 cm). There were 816 (82.6%) patients who underwent oesophagectomy by a left thoracotomy, with the remaining 172 (11.2%) by a right thoracotomy. Their clinicopathological characteristics are demonstrated in Table 1 .
With regard to the 632 (64.0%) patients with pT2-3N0M0, the median age was also 53 years (range: 25-70 years). Of those, 208 (32.9%) were pathological T2 and 424 (67.1%) were T3. According to tumour grade, 162 (25.6%) were well differentiated (G1), 389 (61.6%) moderately differentiated (G2) and 117 (18.7%) poorly differentiated (G3). The distribution of tumour location was nonuniform, with 11 (1.7%) cases in the upper third thoracic segment, 503 (79.6%) in the middle third and 118 (18.7%) in the lower third. There were more tumours with pathological stage IIB in the middle third than in the upper or lower third of the oesophagus (Table 2) . Five-hundred and thirty patients (83.9%) underwent oesophagectomy by a left thoracotomy and 102 (16.1%) by a right thoracotomy (Table 3) .
Prognostic factors analysis
Prognostic factors affecting long-term survival were evaluated and presented in Tables 1 and 3 . For the entire patient group, age (P = 0.84), sex (P = 0.15), tumour grade (P = 0.94) and surgical approach (P = 0.16) were not associated with survival in univariate analysis. However, tumour length (P = 0.0001), tumour location (P = 0.049), pathological T (P < 0.0001), pathological N category (P < 0.0001) and AJCC stage (P < 0.0001) were significantly influenced overall survival in univariate analysis (Table 1) . A multivariate Cox regression model was constructed with the incorporation of tumour length, tumour location, pathological T, pathological N category and TNM stage (seventh). Again, pathological T (P = 0.021), pathological N category (P = 0.010) and AJCC stage (seventh; P = 0.0001) remained as independent prognostic factors ( Table 1) , but tumour location (P = 0.904) and tumour length (P = 0.212) did not have significant influence on survival in multivariate analysis. However, for pT2-3N0M0 patients, univariate analysis indicated that tumour location (P = 0.001), tumour grade (P = 0.0001), surgical approach (P = 0.001), pathological T category (P = 0.034) and seventh edition AJCC stage (P < 0.0001) were significantly associated with patient survival (Table 3) . When tumour location, tumour grade, surgical approach, pathological T category and AJCC stage were included as variables in the multivariate Cox regression analysis, lower location of tumour (P = 0.0001), right thoracotomy (P = 0.020), decreasing pathological T classification (P = 0.0001) and AJCC stage (P < 0.0001) were independent factors favouring survival. In contrast, upper location, left thoracotomy, increasing pathological T classification and AJCC stage were independent factors that adversely affected survival time (Table 3) .
Tumour location and survival
The median survival time of the entire cohort of 988 patients was 32.0 months (95% confidence interval [95% CI], 0.8-128.7 months), with the 1-, 3-, 5-and 10-year overall survival rates of 84.1, 54.0, 44.4 and 35.2%, respectively. Table 1 summarizes that tumour location was associated with patient survival in the univariate analysis (P = 0.049). We also established the survival curves using the Kaplan-Meier method, which indicated that the survival among the three tumour location groups was comparable (P = 0.142, Fig. 1 ). Although the univariate analysis showed that tumour location was significantly associated with patient survival, it was not identified as an independent prognostic factor in multivariable Cox proportional hazard regression analysis (P = 0.904, Table 1 ).
When we focus on patients with pT2-3N0M0 tumours, tumour location strongly predicted survival in both univariate (odds ratio [OR]: 0.63; 95% CI: 0.48-0.84; P = 0.001) and multivariate analyses (OR: 0.53; 95% CI: 0.42-0.67; P = 0.0001; Table 3 ). A significant difference in survival with respect to tumour location was also shown in Kaplan-Meier survival curves (P = 0.004, Fig. 2 ). Median survival times were 38.1 months (95% CI: 13.2-112.3 months) for upper thoracic oesophageal cancer, 46.6 months (95% CI: 0.8-128.2 months) for the middle third and 66.0 months (95% CI: 5.1-128.7 months) for the lower third oesophagus. The lower thoracic tumour showed a better 1-, 3-, 5-and 10-year overall survival rates and median survival time.
The patients with pT2-3N0M0 OSCC were subdivided into three groups by tumour location and tumour grade in the new staging system: lower and well differentiated, stage IB; not lower but well differentiated or lower and not well differentiated, IIA; and not lower and not well differentiated, stage IIB. Kaplan-Meier analysis revealed significant differences among the survival curves. A P-value calculated by the log-rank test was 0.0001, which indicated that the three subgroups have a significantly different prognosis (Fig. 3) . Further pairwise comparison was IB versus IIA (P = 0.008), IB versus IIB (P = 0.008) and IIA versus IIB (P = 0.0002). The seventh edition staging system showed discriminatory ability in predicting survival of patients with pT2-3N0M0 OSCC.
DISCUSSION
The seventh edition staging system is based on a new risk-adjusted random forest analysis of worldwide data and accounts for interactions of anatomical and non-anatomical cancer characteristics, first incorporated tumour location and grade in patients with pT2-3N0M0 [6, 8] . In the current AJCC Cancer Staging Manual, tumour location is redefined as the length between the upper incisor and the upper edge of the tumour, not the epicentre of the tumour. The oesophagus is now divided into cervical, upper thoracic, middle thoracic and lower thoracic regions by the thoracic entrance, inferior border of azygos vein arch and inferior border of inferior pulmonary vein.
However, the clinicopathological presentation of oesophageal carcinoma, including tumour location, histology and age distribution of oesophageal cancer between Western and Asian countries, especially China, is quite different [1] . Adenocarcinoma of the lower oesophagus and the gastroesophageal junction, including the proximal gastric cardia portion, is prevalent in the West. In contrast, OSCC of the thoracic oesophagus is more prevalent in Asia. Unfortunately, Asian patients constituted only 25.2% (1168 of 4627 patients) of the database used to elaborate the seventh AJCC staging system for oesophageal cancer in spite of the truth that more than 50% of oesophageal cancer patients are Chinese. Therefore, several analyses have been published recently, primarily in China, to test whether tumour location should be included as a factor in staging of thoracic OSCC [8] [9] [10] [11] [12] [13] [14] [15] . The first study with reasonable large numbers that examined this variable to our knowledge was reported by Yang et al. [11] . This study retrospectively evaluated 1220 patients who received curative surgical resections, and found that tumour location did not adequately differentiate patients into different staging category subgroups in regard to overall survival of thoracic OSCC in the Chinese population. In their study, the distribution of clinicopathological characteristics, such as sex, surgical approaches, pathological N classification and AJCC staging, in the three tumour location groups was not well balanced. They therefore used subgroup analysis and multivariate Cox regression analysis to test the impact of tumour location on survival prognosis, and assumed that the staging of OSCC in China should be simplified by omitting tumour location as a variable. Unfortunately, the authors did not conduct multivariable Cox regression analysis to assess the correlation between tumour location and long-term survival in the pathological T2-3N0M0 OSCC patients in which tumour location was included in the seventh AJCC staging system for OSCC. Furthermore, it was recommended in a WECC data analysis that a minimum of 10 lymph nodes should be resected for T1 cancer, 20 nodes for T2 cancer and 30 or more nodes for T3/T4 cancers [16, 17] . No doubt exists that the numbers of positive lymph nodes depend on the extent of lymph node sampling. However, in the authors' study, they used an admittance threshold of only seven lymph nodes examined to select patients. This number was very low, and may lead to understage the current TNM classification that is based on number and not location of lymph node metastases.
Situ et al. [9] also reported that tumour location was not an independent prognostic factor in patients with pathological T2N0M0 OSCC using both univariate and multivariate analyses.
However, in their study, the medical records were accomplished before the publication of the seventh edition of the AJCC Cancer Staging Manual, so the relationship between the exact location of tumour and the new anatomical landmarks was not recorded. Therefore, tumour location was retrospectively estimated from endoscopy records that were not anatomical segmentation of oesophageal cancer according to the new stage system. Even if they dichotomized some variables and only considered the three identified combinations of tumour location and histopathological grade (lower and well differentiated, stage IB; not lower but well differentiated or lower and not well differentiated, stage IIA; and not lower and not well differentiated, stage IIB), there might still be insufficient numbers of patients to detect a survival difference [5] .
Before the new AJCC staging system for oesophageal cancer was developed, some previous studies had demonstrated that tumour location did affect survival, consistent with our results [14, 15] . Unfortunately, these findings were either small size of series or inclusion of patients with perioperative chemotherapy or radiotherapy and incomplete resection.
In our study, we attempted to eliminate the effects of neoadjuvant and adjuvant therapy and other inadequate therapy mentioned previously by focusing only on patients who received surgery alone as a treatment. Furthermore, we carefully relocated and defined tumour segmentation according to the description of barium oesophagography and operative documents to conform to the new staging system. The relocation of tumour was not based on endoscopy alone as was addressed in Situ et al. [9] . Our study clearly demonstrated that, in pathological T2-3N0M0 cases, but not in all 988 patients, tumour location was an independent predictor of long-term survival. The association of tumour location with survival was consistent regardless of univariate and multivariate analyses (Table 3 ). In addition, this effect was also presented even when the other standard staging prognostic factors were taken into account. As with pathological T category and AJCC stage, tumour location is an important prognostic factor for OSCC that helps predict long-term survival.
Contrary to the result of pT2-3N0M0 patients, in the entire 988 patients group, tumour location was not an independent prognostic factor in both the Kaplan-Meier method and the multivariate Cox proportional hazard regression analysis, although the univariate analysis showed that it was significantly associated with patient survival. This was in keeping with the results presented in the seventh AJCC staging system, in which tumour location was found to be significant in OSCC patients only with pT2-3N0M0 classification, but not in other pathological stages.
An advantage of our analysis is that we examined the correlation between tumour location and long-term survival in both the entire patient group (n = 988) and the pathological T2-3N0M0 group (n = 632). However, our study has some limitations. First, the relatively small patient numbers in the upper thoracic segment (16/988, 1.6%) may limit statistical power. Secondly, it is a single-institution, retrospective study. It may not be completely valid to directly apply these results to the Asian of even the Chinese oesophageal cancer patients. A good outcome should have a widespread applicability. It seems reasonable to believe that a multi-institutional collaborative study with a large cohort could achieve a more convincing result. Thirdly, most of our patients underwent a left thoracotomy (816/988, 82.6%). The common upper right mediastinal lymph nodes and celiac lymph nodes were difficult to remove through this operative route, although the total numbers resected in the cohort of our study were adequate. 
CONCLUSION
Our data support the inclusion of tumour location in the seventh edition of the AJCC staging system. Tumour location is a strong, independent prognostic factor of long-term survival for pathological T2-3NOMO OSCC in the Chinese population but does not apply to all stages, as indicated in the seventh edition of the AJCC Cancer Staging Manual. Staging of OSCC should not be simplified by omitting tumour location as a variate. Cooperation of more institutions from Asian countries is required to confirm our results.
